Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Putrescine

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Putrescine?

Putrescine is an investigational drug.

There have been 6 clinical trials for Putrescine. The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Prostatic Neoplasms, Colorectal Neoplasms, and Subarachnoid Hemorrhage. The leading clinical trial sponsors are National Cancer Institute (NCI), University Hospital, Bordeaux, and University of Zagreb.

There are three US patents protecting this investigational drug and twenty-seven international patents.

Recent Clinical Trials for Putrescine
Effect of Probiotic Lozenges on Halitosis in Patients With Chronic PeriodontitisBioGaia ABPhase 4
Effect of Probiotic Lozenges on Halitosis in Patients With Chronic PeriodontitisUniversity of ZagrebPhase 4
Feasibility Study on Stem Cells Sensitivity AssayAssociazione Oncologia TraslazionalePhase 2

See all Putrescine clinical trials

Clinical Trial Summary for Putrescine

Top disease conditions for Putrescine
Top clinical trial sponsors for Putrescine

See all Putrescine clinical trials

US Patents for Putrescine

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Putrescine   Start Trial Method of molding plastic products having chemically bonded protective coatings Libbey-Owens-Ford Co. (Toledo, OH)   Start Trial
Putrescine   Start Trial Aryloxytriazine-capped polyphenylene ethers and method for their preparation General Electric Company (Schenectady, NY)   Start Trial
Putrescine   Start Trial Method for producing polyurethanes from poly-(hydroxyalkyl urethanes) Medtronic, Inc. (Minneapolis, MN)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.